EMA Authorised: Obgemsa (vibegron) — Pierre Fabre Medicament

View source ↗

Summary

EMA has authorised Obgemsa (vibegron) for overactive bladder and urinary incontinence. The marketing authorization holder is Pierre Fabre Medicament.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• Obgemsa (vibegron)

Snippet

Status: Authorised. Therapeutic area: Urinary Bladder, Overactive;Urinary Incontinence. MAH: Pierre Fabre Medicament. Decision date: 04/07/2025